Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02654483 · ClinicalTrials.gov registry record · Phase 2
Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
A Phase 2 study of Pruritus and Epidermolysis Bullosa, sponsored by Jean Yuh Tang.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT02654483: Completed Phase 2 study of Pruritus and Epidermolysis Bullosa, sponsored by Jean Yuh Tang.
NCT02654483 is a Phase 2 study of Pruritus and Epidermolysis Bullosa that has completed, run by Jean Yuh Tang. The registered enrollment target is 14 participants, below the 110-participant average among 12 other Pruritus trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02654483, a Phase 2 study of Pruritus and Epidermolysis Bullosa, has completed, sponsored by Jean Yuh Tang.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).
Primary Outcome
Determine the efficacy of Serlopitant compared with placebo on reducing EB-associated daily itch score as measured by patient self-reports using a numeric rating scale (NRS) for itch severity.The NRS is comprised of one item and represents the numbers 0 ("no itch") to 10 ("worst imaginable itch"). Because itch is subjective and can vary day to day, nightly NRS scores were recorded in patients' Itch Diaries. NRS recorded by subject daily, from screening visit through the end of the study. This s
Conditions Studied
Interventions
- OTHER Placebo
- DRUG VPD-737
Study Locations (1)
California
- Stanford - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-08-31 |
| Est. Completion | 2018-07-27 |
| Phase | Phase 2 |
What the finished NCT02654483 record still lists
NCT02654483 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 110-participant average among 12 other Pruritus trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Pruritus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02654483 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02654483 about?
NCT02654483 is a clinical study titled "Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients". Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).
What is the current status of trial NCT02654483?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2016-08-31. Estimated completion is 2018-07-27.
What conditions does trial NCT02654483 study?
This clinical trial studies the following conditions: Pruritus, Epidermolysis Bullosa.
What interventions are being tested in trial NCT02654483?
The interventions under investigation include: Placebo (OTHER), VPD-737 (DRUG).
Who is sponsoring clinical trial NCT02654483?
This trial is sponsored by Jean Yuh Tang, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02654483 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pruritus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02654483's enrollment target sits among peer trials
14 12th of 12 higher than 1 of 12 other Pruritus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pruritus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
COMPLETED · Phase 2
-
A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis
COMPLETED · Phase 2
-
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
COMPLETED · Phase 2
-
B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis
COMPLETED · Phase 2
-
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
RECRUITING · NA
-
VR-PMR for Post-Burn Symptoms
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy